Implications of Recent Advances in Ovarian Cancer

This activity is supported by an educational grant from

Media: Webcast

Estimated time to complete activity: 2.0 hours Release Date: August 16, 2010 \| Expiration Date: August 15, 2011

Introduction

By the end of last year, 21,550 new cases of ovarian cancer (OC) were diagnosed in the United States and almost 75% of these were diagnosed when in advanced stage. In this audiocast, six world-renowned experts discuss the current state of the art for treatment of these patients in the first-line and refractory settings and review recent data presented at the 2010 American Society of Clinical Oncology Annual Meeting. The clinical relevance of the data is highlighted and practical recommendations are provided on choosing the most appropriate initial therapy, whether targeted agents should be used singly or in combination, managing targeted agent toxicities, and the role of maintenance therapy.

Chair

CHAIR - Thomas J. Herzog, MD
Physicians and Surgeons Alumni Professor of Clinical Gynecology and Obstetrics (Endowed Chair)
Director, Division of Gynecologic Oncology
Columbia University Herbert Irving Comprehensive Cancer Center
The NewYork-Presbyterian Hospital
New York, New York
Bio

Faculty

Deborah K. Armstrong, MD
Associate Professor of Oncology, Gynecology
and Obstetrics
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Bio

Robert A. Burger, MD
Professor, Surgical Oncology
Section of Gynecologic Oncology
Director, Women's Cancer Center
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Bio

Robert L. Coleman, MD
Professor & Vice-Chair, Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Bio

Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Creighton University School of Medicine
St. Joseph’s Hospital and Medical Center (a member of Catholic Healthcare West)
Phoenix, Arizona
Bio

Angeles Alvarez Secord, MD
Associate Professor
Division of Gynecologic Oncology
Duke University Medical Center
Durham, North Carolina
Bio

Learning Objectives
At the conclusion of this activity, participants should be able to:

Describe the recent data potentially impacting front-line treatment of ovarian cancer
Select appropriate patients for aggressive front-line therapies
Minimize toxicities when administering targeted agents
Analyze future treatment strategies and clinical trials needed to advance therapeutic progress in ovarian cancer
Define unmet needs and discuss potential clinical trial development to address these needs

Target Audience
The target audience for this program is gynecologic oncologists and medical oncologists who treat ovarian cancer.

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Educational Concepts Group, LLC designates this continuing education activity for 2.0 contact hours (0.20 CEUs) (UAN 0199-0000-10-043-H01P).

Type of activity: Knowledge-based

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period August 16, 2010 through August 15, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech BioOncology.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS

Thomas J. Herzog, MD - CHAIR	Consultant Fees Honorarium	Genentech BioOncology, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc Amgen Inc., GlaxoSmithKline, Johnson & Johnson, Lilly USA, LLC, Merck & Co., Inc., Precision Therapeutics, Inc.
Deborah K. Armstrong, MD	Grants/Research Support Consultant Fees	Agensys, Morphotek, Inc. Abraxis BioScience, Agensys, Amgen Inc., Boeringer Ingleheim, Genentech BioOncology, Morphotek, Inc., Ventirx
Robert A. Burger, MD	Honorarium	Lilly USA, LLC
Robert L. Coleman, MD	Consultant Fees Grants/Research Support Other Financial or Material Support Speakers’ Bureau	Abbott Laboratories, Allos Therapeutics, Inc., BiPar Sciences, Inc., GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Pfizer Inc, sanofi-aventis Abraxis BioScience, Morphotek Inc., Novartis, sanofi-aventis Abraxis BioScience, Amgen Inc., Centocor Ortho Biotech Inc., Daiichi Sankyo Co., Ltd., Genentech, Inc., Merck & Co., Inc., Nektar Centocor Ortho Biotech Inc., Lilly USA, LLC
Bradley J. Monk, MD, FACS, FACOG	Grants/Research Support Honorarium Speakers’ Bureau	GlaxoSmithKline, Johnson & Johnson, sanofi-aventis GlaxoSmithKline, Lilly USA, LLC Lilly USA, LLC
Angeles Alvarez Secord, MD	Grants/Research Support Consultant Fees Honorarium Speakers’ Bureau Other Financial or Material Support	Bristol-Myers Squibb Company, GlaxoSmithKline, Lilly USA, LLC, The Menarini Group, Precision Therapeutics, Inc., sanofi-aventis Abraxis BioScience, Boehringer Ingelheim, Cellectar, Inc., Lilly USA, LLC, sanofi-aventis Lilly USA, LLC GlaxoSmithKline, Lilly USA, LLC Intuitive Surgical, Inc.

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.